Loading...
Loading...
ALVR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 19.6M |
| Operating I/L | -29.1M |
| Other Income/Expense | 1.4M |
| Interest Income | 1.4M |
| Pretax | -18.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -18.3M |
Allovir, Inc. is a clinical-stage cell therapy company specializing in allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for the prevention and treatment of viral-associated diseases. Its lead product, posoleucel, targets various viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. The company also has preclinical and clinical development product candidates for respiratory syncytial virus, influenza, parainfluenza virus, human metapneumovirus, SARS-CoV-2, COVID-19, and hepatitis B. Allovir, Inc. generates revenue through the research, development, and commercialization of its allogeneic VST therapies.
